Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Go back to Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years| Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) | Delayed: 5.95 -0.05 (0.83%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.00 | 52 Week High | $18.00 | |||
| Open | $5.97 | 52 Week Low | $6.91 | |||
| Day High | $6.11 | P/E | N/A | |||
| Day Low | $5.93 | EPS | $-0.67 | |||
| Volume | 584,867 | |||||
